Cancer immunotherapies pipeline made up of 3,100 candidates

There are 3,100 drug candidates being developed in the field of cancer immunotherapy, according to a report from GBI Research.

The company’s latest report states that these drugs encompass more than a third of all candidates in development in oncology, reflecting the excitement in the field as pharma companies seek to replicate the early success of the immune checkpoint inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab).